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Introduction
The illness I am going to discuss bears some relationship to what we have been discussing previously
-that is, basically the problem is one of hemolysis
brought about by a defect in the red cell (Dacie,
1967). However, it differs in several major respects
from the other hemolytic anemias under discussion.
First, the defect is not congenital but rather acquired.
Also, there may be 100 million to 200 million people
with a glucose-6-phosphate dehydrogenase deficiency,
but mercifully paroxysmal nocturnal hemoglobinuria
(PNH) is rarer. The incidence is probably not as low
as has been suspected, but increases as one looks for
the disease. In our own clinic we have, within the last
three years, found 16 patients with PNH, some by
referral to be sure. It is important to identify the patients with PNH because of the implications that are
inherent in treating these patients.
Clinical Presentations of PNH
PNH is probably one of those diseases that is badly
misnamed. With its present name, people tend to think
of PNH only when the patient comes to the physician
complaining of passing dark urine in the morning
which clears by noon. Under this definition, hardly
twenty percent of those patients with PNH would be
ordinarily identified.
It has become apparent that there is a great deal
more wrong with the hematopoiesis of patients with
PNH than was originally thought. This defective
hematopoiesis has two characteristics which may be
manifest in different proportions in different patients.
On the one side, the predominant problem may be
marrow hypoplasia, not simply of the red cells but
also of the white cells and of the platelets (Lewis and
Dacie, 1967). The other hematopoietic problem is
that the cells that are made are defective. The manifestation easiest to investigate is, of course, the defect
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in the red cell which renders it sensitive to the lytic
action of complement. This is traditionally demonstrated by the acidified serum test (Ham and Dingle,
1939). This defect in the red cells leads to hemolysis,
which then leads to hemoglobinuria. It has become
apparent in recent years, though, that the white cells
and platelets are likewise defective (Aster and Enright,
1969).
The classic clinical presentation of the patient with
PNH is, of course, hemoglobinuria (Table I) ; when
it is paroxysmal and nocturnal, it is a striking finding.
But, as I have said, if we relied upon this symptom
we would detect, I suspect, not more than twenty
percent of the patients with the disease. When the
symptom is present, the morning urine may be very
dark indeed and the evening urine may not be clear.
The amount of hemoglobinuria may vary greatly from
day to day. One of our patients who was also a wine
connoisseur, reported his urine in terms of the wine it
most nearly resembled. If the color resembled the
color of Chablis, he was pleased but when it looked
like Port, he became apprehensive.
The more usual presentation of PNH is chronic
hemolysis without, at least to the patient's eye, hemoglobinuria. In any patient with chronic hemolysis, one
ought to look for the presence of PNH.
As we mentioned, the bone marrow hypoplasia may
be a major part of the illness, and PNH may grow out
of patients with bone marrow hypoplasia as a primary
event. The bone marrow hypoplasia may be due to
drugs, as it has become apparent that some patients
taking chloramphenicol may, as they recover, show the
manifestations of PNH (Quagliana, Cartwright and
Wintrobe, 1964). The cytopenia in PNH patients may
be simply leukopenia, and/ or thrombocytopenia, without much anemia. But when the patient is carefully
observed, and blood is carefully examined, the defect
in the red cells may be demonstrated.
Iron deficiency is a common presentation of patients with PNH. Usually the reticulocytosis is higher
than one would expect for a similar degree of iron
deficiency in patients not hemolyzing. This is one of
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the few causes of hemolysis in which the loss of iron
is a major problem, and, therefore, iron deficiency is
not uncommon.
Venous thrombotic phenomena are not uncommon
in patients with PNH, possibly because of the release
of thromboplastic substances during intravascular
hemolysis. These thromboses are not simply the usual
arteriosclerotic variety, such as coronary thrombosis
or cerebral thrombosis. In PNH the thrombi are
usually venous and result in unusual syndromes. Adbominal venous thrombosis may occur in the portal
vein, the splenic vein, or most characteristically the
hepatic veins, leading to the Budd-Chiari syndrome.
The presentation of the hepatic vein thrombosis may be
very insidious in its onset, but many patients that die
of PNH, have evidences of hepatic vein thrombosis.
Cerebral vein thrombosis can lead to very bizarre
neurological syndromes due to cerebral venous or
sinus thromboses.
Finally, a most interesting complication of PNH has
been the occurence of acute leukemia. Dr. Dameshek
predicted many years ago that acute leukemia might
well occur in these patients, and indeed it has been
reported in three patients (Dameshek, 1967) . In all
three, the leukemia is acute myelogenous and the PNH
defect in the red cells disappeared with tqe onset of
leukemia.
Diagn o sis: Demonstra t ion of t he Red Cell Defect
How do we make the diagnosis of PNH? We now
define the disease in terms of the red cell defect which
is manifest as an abnormal sensitivity of the red cells
to lysis by complement. It is present in patients with
PNH, by definition, and leads to the problems of the
hemolysis on which we will now base most of our
remaining discussion.
The sensitivity to complement lysis may be detected
in several ways. In Fig 1, I have illustrated the
way we do this (Rosse and Dacie, 1966) .. To generate
this graph, cells are sensitized with an antibody, anti-I
cold agglutinin in this case, and are lysed with different amounts of normal human serum as a source of
complement. In the ordinary complement titration
using sheep cells, differences in the amount of lysis
reflect not differences in the red cells, since sheep cells
are assumed to be always the same, but rather differences in the amount of complement present. In the
complement sensitivity lysis test illustrated here, the
amount of complement present at a given dilution of
serum is the same since normal human serum is used,
so that differences in lysis will therefore reflect not
differences in the amount of complement, but differences in the sensitivity of the cells to lysis by complement in the presence of antibody.
The cells from a normal patient form a single
straight line in this test when one plots the amount
of complement present on a logarithmic scale against

TABLE I
Clinical Presentation and Complications of Paroxysmal
Nocturnal Hemoglobinuria
1. Nocturnal hemoglobinuria.
2. Chronic hemolytic anemia.
3. Pancytopenia - aplastic anemia.
leukopenia
thrombocytopenia
4. Iron deficiency.
5. Acute myelogenous leukemia.
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Fig 1-The lysis of normal and PNH cells by anti-I and
normal human serum. The single population of normal
cells and the two populations of PNH cells are seen.
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the logarithm of the fraction lysed over the fraction
unlysed (please forgive that way of expressing the data;
it has been a tradition since 1916, at least, for plotting
this sort of thing in order to obtain a straight line) .
The straight line with normal cells indicates that there
is a single population of cells with respect to complement sensitivity. The graph also illustrates that it requii;es very large amounts of complement in order to
lyse these cells. When PNH cells are examined in the
same system, a double curve is obtained. One population of cells is nearly normal, although almost never
entirely normal with respect to their complement lysis
sensitivity. Another population of cells, called the
complement-sensitive cells, are extremely sensitive to
lysis by complement; that is, they require very small
amounts of complement to lyse the cells. The proportion of cells in each population will vary from
patient to patient.
It does not really make any difference what antibody one uses in order to demonstrate this phenomenon. In Fig 2 the same thing is demonstrated
using a rabbit antihuman antibody. Here again, the
normal is a single straight line, and both sensitive and
insensitive populations in PNH cells are demonstrated.
In this instance, the difference between the complement sensitive and the complement insensitive populations is not quite so striking as with the anti-I, but is

10.0

=I

,_-.:::-

1.0
"O
"O

Q)

="' "'
c:
3'
Q)

c:
0

u
0

..t:

:::>
c:
0

u
0

~

0.1

0.011

100
Ml. Human Serum Diluted I in 275

Fig 2-The lysis of normal and PNH cells by rabbit antihuman red cell antibody and human serum.
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nevertheless apparent. From this and other data
(Rosse and Dacie, 1966), we have concluded that the
increase in immune lysis under these circumstances is
not an effect of antibody but rather is due to the fact
that the cells have increased sensitivity to the effect
of complement.
What do we mean by increased sensitivity to the
effect of complement? We mean simply that the completion of the complement sequence is more efficient.
In the normal human red cell, the complement sequence appears to be very inefficient; ie, for every
complement sequence that is begun, few go through
to completion-probably less than 1 in 500 on the
normal cell. In the PNH cell, the chances of a complement sequence, once begun, going through to completion are very much greater although there is still a
considerable amount of inefficiency in the system.
The nature of the defect which leads to this
complement sensitivity is, at the present time, totally
unknown. There is a very interesting set of compounds
which can render cells which are normal to appear
somewhat similar to PNH cells. These are the compounds that contain the reactive thiol groups such as
glutathione, cysteine, and so on. The concentrations
of these compounds that are required are often very
high, however, and the exact relationship of the effect
of these compounds to the defect in a PNH cell is not
at all certain at the present time.
What is the relationship of this complement sensitivity to the phenomena with which we are more
familiar, ie, the diagnosis of PNH from the in vitro
tests that we use, or the clinical syndrome that we
observe in the patient? The diagnosis of PNH is not,
under ordinary circumstances, made by generation of
the complex curves which I have shown. Rather, at
least historically, this diagnosis has been made by the
Ham test, or the acidified-serum lysis test. In the Ham
test, one simply acidifies normal serum and incubates
the cells of the patient to observe whether hemolysis
takes place. It was early observed, by Ham himself,
that anything that destroyed complement (that is, heating the serum, adding agents which would chelate
calcium, and so on) would destroy the ability of that
serum to hemolyze the cells of patients with PNH.
Further evidence that there is a relationship between
the complement lysis and lysis observed in the Ham
test is obtained from electron microscope pictures.
When the cells of patients with PNH are lysed in
acidified serum and examined on the electron microscope, small, round, 100 A defects with the heaped-up
edge which are characteristic of destruction of the
membrane by complement are observed (Rosse, Dourmashkin and Humphrey, 1966).
What initiates the lysis in the Ham test is not at
all certain. There is no demonstrable antibody present
in the normal serum. It is thought that fluid-phase
activation of complement may be sufficient to bring
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about the lysis of the cell. In the early days, it was
proposed that another immune system related to
properdin was responsible for the initiation of complement lysis, and this may still have a certain
amount of validity although the exact nature of this
system is not at all certain (Hinz, 1966) . Nevertheless, the difference between the normal cells and
PNH cells is probably not a difference in the amount
of complement that is added to the cell, but in the
efficiency with which the complement sequences are
able to be completed in order to bring about lysis of
the cell.
It was early observed by Dacie and others that
the amount of lysis in the Ham test was highly variable from patient to patient. When we examined the
relationship between the amount of lysis in the Ham
test and the proportion of complement-sensitive cells
present in patients with PNH, we found that, in general, the percentage lysis in the Ham test is less than
the proportion of complement-sensitive cells. In addition, different specimens of normal serum may tend
to lyse different numbers of cells. In most instances
the complement-sensitive population is not entirely
lysed on the first exposure to normal acidified serum.
However, on exposure a second or third time, the
entire complement-sensitive population maY, be lysed.
If the complement-sensitive population is very small,
the lysis may not be detected in the Ham test; this
has occurred in three patients in our experience. In
general the Ham test is a reasonably good screen,
although it is rather cumbersome when done with all
controls. It does detect most patients with PNH, but
does not quantitate very well the proportion of the
complement-sensitive population.
In addition to the false negative test, there is a
"false-positive" acidified serum lysis test. This occurs
in a group of patients, first described in detail by the
Crookstons in Toronto (Crookston, et al, 1969) and
by Vervilghin in Belgium, who have a congenital
defect in erythropoiesis, characterized by a dyserythropoietic anemia, multi-nucleated red cell precursors, and a membrane defect. The membrane
defect is manifest in three ways. First, it makes the
cell more complement-sensitive than normal, but the
complement sensitivity is distributed in the single
population, and the complement sensitivity increase is
five to six times normal rather than 30 times normal
as seen in PNH. Second, an antigen is exposed on the
red cell surface which is not present on normal cells,
and to which normal people have isoantibodies. The
reaction of a naturally occurring antibody present
in most normal serum, together with a modest increase in complement sensitivity, renders the acidified lysis test positive with these cells. However, the
serum of these patients does not contain the antibody,
and therefore their own cells will not lyse in their
own serum, despite acidification.

More recently, Drs. Hartmann and Jenkins at
Nashville have introduced the sucrose lysis test, which
likewise appears to depend upon complement lysis
(Hartmann and Jenkins, 1966). The reduction in
ionic strength increases the efficiency of several of
the steps in the complement sequence. Therefore, by
incubating the cells in the presence of normal serum,
the complement-sensitive cells in PNH will lyse. With
this test there is a much better correspondence between the percentage of cells in the complementsensitive population, and the amount of lysis that
one obtains, although the degree of variabiHty is
somewhat greater than in the acidified serum test.
To date, we have not found any false negatives in
patients with PNH having small complement-sensitive
populations which do not lyse in the sucrose lysis
test. There are, on the other hand, instances of falsepositives of which one must be aware. The cells of
patients with immune hemolytic anemia in which
the antibody can fix complement may lyse, if the cells
are incubated in their own serum and sucrose. However, if the cells are incubated in someone else's type
compatible serum, lysis will usually not occur.
We have related the in vitro phenomena that we
commonly associate with PNH to the complementsensitive population. In order to relate these to
in vivo phenomena, we have investigated the life
span of the red cells in PNH. If the complementsensitivity has anything to do with the hemolysis that
one observes, then there should be a difference in the
life span of the complement-sensitive cells, compared
to the complement-insensitive cells.
If the life span of the red cells is determined using
glycine-2-C,, as a cohort label, the complementsensitive cells are seen to be destroyed extremely
quickly in a random fashion. The half-time of this
random destruction is in the order of four to six days,
indicating that the life span of an individual complement-sensitive cell may be extremely short. The
complement-insensitive cells are also lysed in a random fashion to a far greater extent than normal.
Ordinarily, less than five percent of normal cells are
lysed before reaching senescence. In PNH, probably
25 percent of the complement-insensitive cells are lysed.
Those cells that miss the random destruction process
are destroyed at approximately 110 to 120 days. The
complement-sensitive cells do not become complement
insensitive, since as the complement-sensitive population is lysed and falls, the amount of label in the
whole population falls, indicating that the cells in
the complement-sensitive population are born bad
and die young.
We have also studied the red cell life span of both
populations of cells with DFP32, Again, the life span
of the complement-sensitive cells was much shorter
than that of the complement-insensitive cells, reaffirming that the complement-sensitive cells are de61
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stroyed more rapidly than are the complementinsensitive cells. However, the life span of the
complement-insensitive cells is shorter than normal,
again demonstrating that these cells are not normal.
So, we can see then that the lysis of the complementsensitive cells is an important in vivo correlation to
an in vitro demonstration of complement-sensitivity.
Determinants of the Rate of Hemolysis
One might ask, on what does the daily rate of
hemolysis depend? In Table II, we have listed some
of the things which appear to determine the amount
of hemolysis in patients with PNH. In the first place,
probably the most important parameter is the proportion of complement-sensitive cells. Among most
patients with PNH, the sensitivity to complement' of
this population is nearly the same. In general, those
patients with a high proportion of complementsensitive cells have a higher rate of hemolysis. On
the other hand, an occasional patient does have a
complement-sensitive population which, instead of
being 15-25 times more sensitive than normal, is
5- 7 times more sensitive. These patients have less
hemolysis and less difficulty with th~ disease. Thus, on
rare occasions, the decreased sensitivity of the
complement-sensitive population may spare the patient
some of the trial and tribulations of the disease.
On occasion, the complement-insensitive cells may
also be markedly abnormal. If this population is more
sensitive to complement than usual, then the rate of
hemolysis may in part depend upon destruction of
cells in the population.
Another important determinant of the amount of
hemolysis is the rate of erythropoiesis. The proportion of precursors of cells in the complement-sensitive

TABLE II
Determinants of Hemolysis in Patients with Paroxysmal
Nocturnal Hemoglobinuria
1. Cellular Abnormality.
a. Proportion of complement-sensitive cells.
b. Sensitivity of complement-sensitive cells.
c. Sensitivity of complement-insensitive cells.
2. Rate of Erythropoiesis.
a. Response to iron therapy.
b. Response to androgen therapy.
3. Initiating Mechanisms.
a. Immunologic phenomena.
i. infections-especially viral
ii. vaccinations
b. Drugs- ? heparin.
c. Unknown.
i. nocturnal-acting.
ii. others.
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Fig 3-The effect of iron therapy on the rate of hemolysis
in a patient with PNH.

population is far greater than the proportion of these
cells in the peripheral blood. Therefore, each day a
large number of complement-sensitive cells are delivered to the circulation. If the ability to make red
cells is increased, the number of complement-sensitive
red cells that are delivered to the circulation, and thus
the number that are susceptible to hemolysis is increased. Thus patients who are iron deficient with
PNH may have a bout of hemoglobinuria when given
iron because of the increase in erythropoiesis.
Fig 3 illustrates a patient with iron deficiency who,
after initial studies, was given intrav.e nous iron. The
reticulocyte count did not increase until four to five
days later. It was only when the reticulocyte count began to increase that there was an increase in urine
hemoglobin. As the reticulocyte count rose, the amount
of urine hemoglobin rose precipitously. During this
time, the hematocrit rose and the percentage of complement-sensitive cells rose somewhat. At this point,
the patient began to have abdominal pains, a fairly
frequent complication of a hemolytic episode in patients with PNH, probably due to minor thromboses
in the mesentery and the gut wall. The patient was
transfused, and the reticulocyte count and the urine
hemoglobin fell . He was next given iron dextran and
did not have a hemolytic response because erythropoiesis had been suppressed by elevation of the hematocrit by transfusion. Thus we were able to demonstrate that the hemoglobinuria which follows iron
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therapy is not due to a toxic effect of the iron, but
rather due to a sudden increase in erythropoiesis. We
have seen the same effect in patients given androgens,
but the hemolytic episode is not so abrupt or so
dramatic as in iron therapy.
Other determinants initiating hemolysis are not well
known. Some are immunologically related, since the
red cells are susceptible to immunologic lysis. One
would expect that if immunologic reactions were
going on in the patient, hemolysis might be increased.
This is, in fact, true. Certain virus infections, especially the Hong Kong flu, vaccinations, especially
typhoid vaccinations, and some bacterial infections
have been incriminated as precipitating crises in
hemolytic epjsodes.
The cause of the nocturnal variation is totally unknown. It was originally thought that maybe there
was an accumulation of acid during sleep which
would then mimic the acidified serum lysis test. This is
probably not true. It has also been suggested that the
diurnal variation might be related to diurnal variations
in erythropoiesis. This is difficult to demonstrate, but
it may be true. Most of the time, we do not know
why patients with PNH have a paroxysm of hemoglobinuria.
Summary

I have tried to summarize some of the facts we
know, and some of the questions we need to ask
in a disease which, although it is not common, probably is not as rare as we once thought. Once the
diagnosis is made, one must be very careful in tending
to the patients, since there are instances in which they
react much differently than would normal peopleeither by the hemolytic episode or with other complications. This is especially true with regard to surgery, which may be extremely dangerous in these patients. The post-operative course may be complicated
by thrombosis, infections, and other forms of morbidity. Identification of these patients is important,
simple, and relatively helpful in their care.
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